COMPARATIVE SURVIVAL OUTCOMES BETWEEN ATYPICAL LIVER RESECTION AND HEMIHEPATECTOMY IN CHILDREN WITH HEPATOBLASTOMA

Authors

  • Ziyoyeva Gulrukh Pulatovna,Urinbekova Elmira Muratovna,Xasanov Nosir Abdusoliyevich,Tolmasov Ruzibek Tolmasovich,Azimova Masuda Karimovna Tashkent State Medical University, Department of OSTA and Human anatomy assistant PhD,Tashkent State Medical University, Department of OSTA and Human anatomy assistant,Tashkent State Medical University, Department of OSTA and Human anatomy assistant,Tashkent State Medical University, Department of OSTA and Human anatomy assistant PhD,Tashkent State Medical University, Department of OSTA and Human anatomy associate professor Author

Keywords:

hepatoblastoma; pediatric liver tumors; atypical liver resection; hemihepatectomy; survival; pediatric oncology; liver surgery.

Abstract

Background

Hepatoblastoma is the most common primary malignant liver tumor in children. Complete surgical resection combined with platinum-based chemotherapy remains the cornerstone of curative treatment. However, the optimal extent of liver resection remains controversial, particularly regarding oncological outcomes and postoperative morbidity.

Objective

To compare survival outcomes, recurrence rates, and postoperative complications between atypical liver resection and hemihepatectomy in pediatric patients with hepatoblastoma.

Materials and Methods

A retrospective comparative study was conducted involving pediatric patients diagnosed with hepatoblastoma who underwent surgical treatment between 2015 and 2025. Patients were divided into two groups according to surgical approach: atypical liver resection (Group I) and hemihepatectomy (Group II). Overall survival (OS), disease-free survival (DFS), postoperative complications, and recurrence rates were analyzed. Survival analysis was performed using the Kaplan–Meier method, and comparisons were assessed with the log-rank test.

Results

A total of 62 pediatric patients were included in the study. Group I consisted of 28 patients who underwent atypical liver resection, while Group II included 34 patients treated with hemihepatectomy. The 5-year OS was 82.1% in Group I and 88.2% in Group II (p > 0.05). Disease-free survival reached 71.4% and 79.4%, respectively. Local recurrence was observed more frequently following atypical resection (17.8%) compared with hemihepatectomy (8.8%). Major postoperative complications occurred more commonly after hemihepatectomy, including transient liver insufficiency and biliary leakage.

Conclusion

Both atypical liver resection and hemihepatectomy provide satisfactory long-term survival in children with hepatoblastoma when complete tumor removal is achieved. Atypical resection offers the advantage of preserving functional liver parenchyma, whereas hemihepatectomy demonstrates superior local disease control in advanced tumors. Surgical strategy should be individualized according to PRETEXT stage, vascular involvement, and future liver remnant volume.

References

1.Feng J, Lopez-Terrada D, Geller JI. Surgical management and survival outcomes in pediatric hepatoblastoma. JAMA Network Open. 2019;2(9):e191074.

2.Czauderna P, Haeberle B, Hiyama E, et al. The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma. Cancer. 2016;122(3):338–344.

3.Meyers RL, Tiao GM, de Ville de Goyet J, et al. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Current Opinion in Pediatrics. 2014;26(1):29–36.

4.Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. 2002;95(1):172–182.

5.Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma. Journal of Clinical Oncology. 2005;23(6):1245–1252.

6.Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. Lancet Oncology. 2009;10(6):515–524.

Downloads

Published

2026-06-08